Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensiti
Roche announced the FDA has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer. December 07, 2016